Euglena Co Ltd
TSE:2931
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Walmart Inc
NYSE:WMT
|
Retail
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
396
770
|
Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
UnitedHealth Group Inc
NYSE:UNH
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Walmart Inc
NYSE:WMT
|
US | |
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one Euglena Co Ltd stock under the Base Case scenario is 415.01 JPY. Compared to the current market price of 412 JPY, Euglena Co Ltd is Undervalued by 1%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Euglena Co Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for Euglena Co Ltd cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Euglena Co Ltd
Balance Sheet Decomposition
Euglena Co Ltd
Current Assets | 29.4B |
Cash & Short-Term Investments | 19.8B |
Receivables | 3.8B |
Other Current Assets | 5.8B |
Non-Current Assets | 42.2B |
Long-Term Investments | 722m |
PP&E | 6.2B |
Intangibles | 34.2B |
Other Non-Current Assets | 1B |
Current Liabilities | 12.2B |
Accounts Payable | 1.3B |
Accrued Liabilities | 254m |
Other Current Liabilities | 10.6B |
Non-Current Liabilities | 28.9B |
Long-Term Debt | 21.8B |
Other Non-Current Liabilities | 7.1B |
Earnings Waterfall
Euglena Co Ltd
Revenue
|
47.7B
JPY
|
Cost of Revenue
|
-14.7B
JPY
|
Gross Profit
|
32.9B
JPY
|
Operating Expenses
|
-33.3B
JPY
|
Operating Income
|
-345m
JPY
|
Other Expenses
|
-2.1B
JPY
|
Net Income
|
-2.4B
JPY
|
Free Cash Flow Analysis
Euglena Co Ltd
JPY | |
Free Cash Flow | JPY |
Profitability Score
Profitability Due Diligence
Euglena Co Ltd's profitability score is 40/100. The higher the profitability score, the more profitable the company is.
Score
Euglena Co Ltd's profitability score is 40/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Euglena Co Ltd's solvency score is 42/100. The higher the solvency score, the more solvent the company is.
Score
Euglena Co Ltd's solvency score is 42/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Euglena Co Ltd
According to Wall Street analysts, the average 1-year price target for Euglena Co Ltd is 612 JPY with a low forecast of 606 JPY and a high forecast of 630 JPY.
Dividends
Current shareholder yield for Euglena Co Ltd is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
euglena Co., Ltd. engages in the research, development, production and sale of microalgae products. The company is headquartered in Minato-Ku, Tokyo-To and currently employs 883 full-time employees. The company went IPO on 2012-12-20. The firm masters the core technology of euglena, which provides the edibility of microalga euglena (Japanese name: Midorimushi) and the technology of outdoor large-scale cultivation. The firm operates in two business segments. The Healthcare segment is involved in the original equipment manufacturer (OEM) provision of food and cosmetics using euglena, as well as the planning and sale of products. The Energy and Environment segment is involved in the technology development and commissioned research of euglena and other microalgae, as well as the research and development of biofuels for the future commercialization.
Contact
IPO
Employees
Officers
The intrinsic value of one Euglena Co Ltd stock under the Base Case scenario is 415.01 JPY.
Compared to the current market price of 412 JPY, Euglena Co Ltd is Undervalued by 1%.